Table 1 Baseline characteristics of the AGES study participants, stratified by incident myocardial infarction (MI)

From: Circulating causal protein networks linked to future risk of myocardial infarction

Characteristic

Variable*

Free of MI

Incident MI

P-value

Total

Demographics

Numbers

4051 (86.8)

618 (13.2)

N/A

4669

Females (%)

2507 (61.9)

299 (48.4)

3E-10

2806 (60.1)

Age (years)

76.14 (5.46)

78.64 (5.70)

3E-24

76.44 (5.56)

Anthropometry

BMI (kg/m2)

27.05 (4.49)

27.04 (4.22)

0.975

27.05 (4.46)

BMI category

–

–

0.267

–

BMI < 25 kg/m2

1371 (33.9)

194 (31.4)

 

1565 (33.5)

BMI = 20-30 kg/m2

1769 (43.7)

291 (47.2)

 

2087 (44.7)

BMI > 30 kg/m2

909 (22.4)

132 (21.4)

 

1041 (22.3)

SAT (cm2, CT)

260.50 (113.35)

245.68 (104.99)

0.003

258.85 (112.38)

VAT (cm2, CT)

169.62 (78.65)

180.19 (83.53)

0.002

170.91 (79.38)

Lifestyle

Smoker

–

–

0.039

–

Never

1770 (44.8)

236 (39.3)

 

2006 (43.0)

Former

1713 (43.3)

282 (47.0)

 

1995 (42.7)

Current

472 (11.9)

82 (13.7)

 

554 (11.9)

Physiological

DBP (mmHg)

79.98 (10.71)

80.64 (10.78)

0.174

80.06 (10.71)

SBP (mmHg)

151.15 (22.29)

155.94 (24.10)

4E-06

151.76 (22.59)

eGFR (ml/min/1.73m2)

65.19 (15.06)

59.96 (16.18)

2E-13

64.51 (15.30)

Cardiovascular imaging

CAC

203.5 [26.9, 684.5]

677.6 [195.5, 1609.1]

3E-49

236.2 [34.8, 786.9]

TAC

202.5 [20.6, 826.7]

556.9 [101.3, 1549.5]

2E-20

229.8 [25.9, 906.4]

Plaque severity

2400 (64.0)

450 (79.1)

3E-13

2850 (61.0)

Metabolic

T2D

432 (10.7)

99 (16.0)

2E-04

531 (11.4)

MetS

782 (19.3)

144 (23.3)

0.023

926 (19.8)

HbA1c

0.48 (0.09)

0.50 (0.10)

1E-04

0.49 (0.09)

Incident NAFLD

37 (5.6)

9 (9.7)

0.185

46 (0.98)

HDLC (mmol/L)

1.62 (0.45)

1.53 (0.45)

2E-07

1.61 (0.45)

LDLC (mmol/L)

3.56 (1.01)

3.55 (1.07)

0.848

3.56 (1.02)

TG (mmol/L)

1.03 [0.78, 1.41]

1.08 [0.78, 1.53]

0.019

1.04 [0.78, 1.42]

Medication

Lipid lowering

699 (17.3)

151 (24.4)

3E-05

850 (18.2)

Antihypertensive

2406 (59.4

448 (72.5)

3E-10

2854 (61.1)

Cardiovascular and follow-up

Incident CHD

384 (9.5)

476 (77.0)

2E-274

860 (18.4)

Incident HF

188 (4.6)

159 (25.7)

3E-55

347 (7.4)

Incident Stroke

368 (9.1)

54 (8.7)

0.838

422 (9.0)

Follow-up (years)

9.9 [8.1, 11.0]

5.6 [2.8, 8.2]

6E-136

9.7 [6.8, 10.8]

  1. *Continuous variables were compared with two-sample t tests or Wilcoxon rank-sum tests, as appropriate, and categorical variables with the Chi-square test. Numbers are mean (SD) for continuous-, N (%) for categorical- and median [IQR] for skewed variables. All P-values reported are two-sided. The LDL cholesterol and blood pressure readings were adjusted for lipid-lowering and antihypertensive medications, respectively. Abbreviations: BMI body mass index, SAT subcutaneous fat by CT, VAT visceral fat by CT, SBP systolic blood pressure, DBP diastolic blood pressure, HDLC HDL cholesterol, LDLC LDL cholesterol, TG triglyceride, FG fasting blood glucose, HbA1c glycated hemoglobin, T2D type 2 diabetes, MetS metabolic syndrome, NAFLD non-alcoholic fatty liver disease, CHD coronary heart disease, MI myocardial infarction, HF heart failure, CAC coronary artery calcium, TAC thoracic aortic calcium; Plaque, carotid plaque severity (carotid plaque was assessed in 5017 individuals of the AGES cohort); N/A not applicable.
  2. All participants were measured for 7523 proteins in serum. The table was generated after removing all prevalent MI cases.
Back to article page